Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $37
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $35 to $37.
Barclays analyst Etzer Darout maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $35 to $37.